Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS2 | P35354 | 2/20 | 0.56 |
| ▸ | MEN1 | O00255 | 2/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.49 |
| ▸ | LMNA | P02545 | 1/20 | 0.49 |
| ▸ | MAPT | P10636 | 2/20 | 0.46 |
| ▸ | KDM1A | O60341 | 5/20 | 0.45 |
| ▸ | FNTA | P49354 | 2/20 | 0.45 |
| ▸ | FNTB | P49356 | 2/20 | 0.45 |
| ▸ | PIM1 | P11309 | 1/20 | 0.44 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.44 |
| ▸ | BCHE | P06276 | 2/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | TP53 | P04637 | 1/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23936708 | 0.84 | PTGS2 (0.60) | PTGS2MEN1KMT2ALMNAKDM1A | |
| SCHEMBL14697664 | 0.81 | LMNA (0.60) | PTGS2MEN1KMT2ALMNAMAPT | |
| SCHEMBL21196596 | 0.78 | PIM1 (0.68) | LMNAMAPTKDM1APIM1ALDH1A1 | |
| SCHEMBL19745606 | 0.78 | PIM1 (0.51) | MEN1KMT2ALMNAMAPTKDM1A | |
| SCHEMBL17419212 | 0.78 | KDM1A (0.58) | LMNAMAPTKDM1APIM1ALDH1A1 | |
| SCHEMBL9100289 | 0.78 | MAPT (0.50) | PTGS2MEN1KMT2ALMNAMAPT | |
| SCHEMBL28586304 | 0.77 | PIM1 (0.54) | LMNAMAPTKDM1APIM1ALDH1A1 | |
| SCHEMBL28593684 | 0.76 | PDF (0.53) | LMNAMAPTKDM1APIM1ALDH1A1 | |
| SCHEMBL28393566 | 0.76 | PDF (0.53) | LMNAMAPTKDM1APIM1ALDH1A1 | |
| SCHEMBL28889573 | 0.76 | PDF (0.53) | LMNAMAPTKDM1APIM1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3475277-B1 | ANTI-INFECTIVE HETEROCYCLIC COMPOUNDS AND USES THEREOF | BIOIMICS AB (SE) | 2021-10-20 | — | — | EP | disclosed |
| US-11130741-B2 | Anti-infective heterocyclic compounds and uses thereof | BIOIMICS AB (SE) | 2021-09-28 | — | — | US | disclosed |
| US-20190233384-A1 | ANTI-INFECTIVE HETEROCYCLIC COMPOUNDS AND USES THEREOF | BIOIMICS AB (SE) | 2019-08-01 | — | — | US | disclosed |
| EP-3475277-A1 | ANTI-INFECTIVE HETEROCYCLIC COMPOUNDS AND USES THEREOF | Bioimics AB (SE) | 2019-05-01 | — | — | EP | disclosed |
| WO-2017222466-A1 | ANTI-INFECTIVE HETEROCYCLIC COMPOUNDS AND USES THEREOF | BIOIMICS AB (SE) | 2017-12-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190233384-A1 | ANTI-INFECTIVE HETEROCYCLIC COMPOUNDS AND USES THEREOF | ELANE, MPO, NISCH | PTGS2 107/4885MEN1 2160/4885KMT2A 4554/4885 |
| US-11130741-B2 | Anti-infective heterocyclic compounds and uses thereof | ELANE, MPO, NISCH | PTGS2 107/4885MEN1 2160/4885KMT2A 4554/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.